Melanoma Institute Australia welcomes new CEO Matthew Browne
9 August 2018
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
Matthew, who takes up the position effective immediately, brings to the organisation a wealth of experience in managing organisations involved in health care and major infrastructure projects.
He has been with Melanoma Institute Australia since January 2017, having performed the roles of Chief Financial Officer and Company Secretary, and more recently Acting CEO. Prior to joining Melanoma Institute Australia, Matthew was Acting CEO for Cure Brain Cancer Foundation and held a variety of senior executive roles responsible for Transport NSW’s Opal smartcard ticketing project, including Director of Ticketing.
Matthew holds a Bachelor of Economics from Macquarie University and has been a member of the Institute of Chartered Accountants in Australia since 1990.
Chairman of Melanoma Institute Australia, Mr Grant King said; “We are excited to welcome Matthew as CEO of Melanoma Institute Australia as his leadership skills and experience in the medical research and not for profit sectors will ensure the organisation continues to be a world leader in melanoma prevention, treatment and cure.”
“Given Matthew’s previous executive roles, including at Melanoma Institute Australia, we are confident his transition into the CEO role will be smooth and effective and the organisation will continue its momentum towards its mission of zero deaths from melanoma,” he said.
“I am delighted and honoured to be leading such a world-class organisation,” Matthew Browne said. “I am proud of the achievements made by Melanoma Institute Australia over many years, providing patients with melanoma the very best standard of care and more life-saving treatment options.
“Melanoma Institute Australia is deeply committed to achieving its mission, and it will truly be a time to celebrate when that day arrives,” he said.
For more information, please contact:
Jennifer Durante |Melanoma Institute Australia | 0412 798 990 | email@example.com
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.